Morphotek has built a diverse preclinical pipeline of monoclonal antibodies with potential applications in oncology, inflammatory disease, and infectious disease/ biodefense therapeutic areas.

MORAb-028

MORAb-028 is an investigational fully human IgM monoclonal antibody that targets a cell surface glycolipid named diacyl ganglioside (GD2), which is expressed in lung and neuroectodermal tumors such as melanomas, neuroblastomas, small cell lung carcinomas (SCLCs), and many sarcomas.

MORAb-047 is an investigational humanized IgG monoclonal antibody that targets Botulinum toxin, an extremely potent and lethal neurotoxin with potential for use as a biological weapon against civilian or military populations. A precursor to MORAb-047 was discovered by collaborators at the United States Army Medical Research Institute.

KANAb-071 is an investigational humanized IgG monoclonal antibody that targets a soluble chemokine thought to be involved in a crucial pathway leading to inflammatory disease.  The antibody has shown activity in preclinical models of rheumatoid arthritis and dermatitis preclinical models. KANAb-071 is being investigated in collaboration with KAN Research Institute (Eisai) and Human Genome Sciences. 

 

The information contained herein is investigational and is not intended to make claims of safety or efficacy prior to approval by the FDA or other regulatory authorities. There is no guarantee that the agents described or their uses will be approved by the FDA or other regulatory authorities.